Acumen Diagnostics' PCR capabilities to tackle Omicron COVID-19 variant
2021年12月3日 - 3:00PM
JCN Newswire
Homegrown medical technology Company, Acumen Diagnostics Pte.
Ltd. ("Acumen Diagnostics" or the "Company"), a 51% owned
subsidiary of Q&M Dental Group (Singapore) and 49% owned by
Aoxin Q&M Dental, today announced that its proprietary,
locally-manufactured polymerase chain reaction ("PCR") test kits
Acu-Corona 2.0 and Acu-Corona Duplex are able to detect COVID-19
positive cases infected with the Omicron variant.
Dr Ong Siew Hwa, Executive Director of Aoxin Q&M Dental and
Chief Executive Officer & Chief Scientist of Acumen Diagnostics
said, "As the COVID-19 threat continues to evolve with the
emergence of a potentially more transmissible variant, Omicron,
highly-accurate and cost-effective COVID-19 testing becomes even
more important to detect and help curb the spread of the virus.
With PCR tests remaining the gold standard to detect COVID-19,
Acumen Diagnostics remains well-positioned to help Singapore tackle
this new challenge posed by the virus, with our effective and
affordable PCR test kits that are equipped to detect COVID-19
positive cases infected with Delta and Omicron, as well as our
laboratory testing capabilities that can run 7000 tests daily. We
will continue to contribute to national COVID-19 testing efforts to
support Singapore's safe and sustainable re-opening."
In addition to detecting COVID-19 positive cases infected with the
Delta variant, the Company's proprietary PCR test kits are able to
detect COVID-19 positive cases infected with the Omicron variant as
well.
The Acu-Corona 2.0 PCR test targets two COVID-19 genes - RdRp and
E, while the Acu-Corona Duplex PCR test targets the E gene and S
gene. The portion of the S gene targeted by the Acu-Corona Duplex
PCR test does not contain any of the 32 mutations that occurred in
the Omicron variant, hence it can detect the Omicron variant
without any loss of sensitivity.
This proprietary technology used in PCR test kits and laboratory
testing is developed and owned by Acumen Diagnostics. Being locally
manufactured, the Company's test kits can be deployed quickly and
are more cost-effective and allow for greater self-sufficiency,
compared to that of its peers imported from overseas.
Acumen Diagnostics possesses deep technical capabilities and the
supporting infrastructure in molecular diagnostics, spanning
R&D, manufacturing, and clinical laboratory testing, with 2
laboratories that are able to process 7000 COVID-19 diagnostics
tests daily.
About Acumen Diagnostics Pte. Ltd.
Acumen Diagnostics Pte. Ltd. ("Acumen Diagnostics") is a homegrown
Singaporean, award-winning medical technology company. It is fully
integrated with functions in research and development,
manufacturing, as well as commercialisation of molecular
diagnostics by distribution as well as conducting clinical
laboratory testing services for (including but not limited to)
infectious diseases, cancer, and COVID-19. It has also actively
established frontline services such as COVID-19 on-site swabbing
operations.
Acumen Diagnostics is a 51% subsidiary of SGX-listed Q&M Dental
Group (Singapore) Limited (SGX: 1D4.SI) and 49%-owned by SGX-listed
Aoxin Q&M Dental Group Limited (SGX: QC7.SI). For more
information, please visit the company website at
www.acumen-research.com.
For more information, please contact:
Waterbrooks Consultants Pte. Ltd.
+65 6958 8008, query@waterbrooks.com.sg
Wayne Koo (M): +65 9338 8166, wayne.koo@waterbrooks.com.sg
Derek Yeo (M): +65 9791 4707, derek@waterbrooks.com.sg
Copyright 2021 JCN Newswire . All rights reserved.